Phoenix Bio-Tech Corp is releasing Trep-Sure™, the next-generation enzyme immunoassay (EIA) for syphilis. Unlike many current algorithms based on anticardiolipin testing, Trep-Sure uses a cocktail of highly purified immunodominant Treponemal recombinant antigens to eliminate false-positive reactions such as ANA, lyme, and rheumatoid factor. Its high sensitivity (0.02 IU/mL) makes Trep-Sure ideal as a first-line assay in diagnostic and blood-screen settings. The test requires 100 uL of undiluted plasma or serum. Incubations occur at 37ÞC. The flexibility of various parameters accommodates manual and automated EIA platforms. Trep-Sure employs HRPO and TMB as the indicator system.
Phoenix Bio-Tech Corp
(905) 826-6330; www.phoenixbiotech.com